Sutura, Inc.
OTC Bulletin Board : SUTU

Sutura, Inc.

November 04, 2005 08:38 ET

SuperStitch Developer Sutura Announces Promotion of Tom Lindsey to Vice President Sales and Marketing

FOUNTAIN VALLEY, CALIFORNIA--(CCNMatthews - Nov. 4, 2005) - Sutura, Inc. ("Sutura") (OTCBB:SUTU), a California-based medical device company, today announced the promotion of Tom Lindsey to the position of Vice President Sales and Marketing. This appointment comes on the one-year anniversary of Mr. Lindsey joining Sutura, and as the Company starts to see the success of the sales and marketing program for its 'As Simple As 1-2-3' SuperStitch to medical facilities, hospitals and Cath-Labs nationwide.

In making the announcement, Anthony Nobles, President and Chief Executive Officer at Sutura, Inc, said, "The appointment of Tom Lindsey as our Vice President Sales and Marketing is the result of his hard work and dedication in establishing our sales and marketing team in the U.S. As the Director of U.S. Sales & Marketing, Mr. Lindsey has quickly made an impact and become a key leader in our organization. The results of his efforts, particularly in establishing our sales and marketing strategy and fostering a seamless sales culture throughout Sutura, have contributed to the sale of the SuperStitch to cath-labs and other medical facilities."

Tom Lindsey has over 25 years of experience in sales, marketing, general management and product development in the medical industry. Prior to joining Sutura, Lindsey was the Vice President of Sales for two different national biomedical equipment companies, one with annual revenues of $100,000,000. In addition, he has owned two medical device companies, and hired and trained sales forces on a regional and national level. Tom has a B.S. Degree in Microbiology from Brigham Young University and is a graduate of multiple business and sales seminars including Xerox, PSS, Wilson Learning, SRI, and Franklin Time Management.

"It has been exciting and rewarding to help oversee the transition of Sutura into a sales oriented medical device company," said Tom Lindsey, newly appointed Vice President Sales and Marketing at Sutura. "Over the past few months this has meant getting in front of an increased number of qualified customers and introducing them to the SuperStitch, as well as being in a position to attract some of the top vascular product sales representatives in the country."

About Sutura, Inc.

Sutura®, Inc. (www.suturaus.com) is a medical device company that has developed a line of innovative, minimally invasive, vascular suturing devices to suture the puncture created in arteries during open surgery and catheter-based procedures. The Company's line of SuperStitch medical devices provide sutured closure of the arteriotomy site utilizing the existing catheter sheath introducer or cannula during fluoroscopically guided procedures and directly through the open arteriotomy during open surgical procedures.

Within the United States the 8F & 6F SuperStitch devices are available for use in performing vascular stitching in general surgery, including endoscopic procedures. It is not intended for blind closure of an arteriotomy site. The SuperStitch 8F & 6F is approved in the European Union and CE marked with the indication for use as follows: The SuperStitch is indicated for use in performing vascular stitching in general surgery, including endoscopic procedures. In the EU there is no requirement for the use of fluoroscopic guidance. Sutura's headquarters are in Fountain Valley, California. "Sutura®" and "SuperStitch®" are registered trademarks of Sutura, Inc.

Forward-Looking Information Is Subject to Risk and Uncertainty

Certain statements in this press release may contain projections or "forward-looking" information (as defined in the Private Securities Litigation Reform Act of 1995) that involve risk and uncertainty. The words "aim", "plan", "likely", "believe", "expect", "anticipate", "intend", "estimate", "will", "should", "could", "may", "appears", and other expressions that indicate future events and trends identify forward-looking statements. These statements are not guaranties of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are based upon assumptions as to future events that may not prove to be accurate. Actual outcomes and results may differ materially from what we express or forecast in these forward-looking statements. As a result, these statements speak only as of the date they were made and we undertake no obligation to publicly update or revise any forward-looking statements. Our actual results and future trends may differ materially from our forward-looking statements depending on a variety of factors including the acceptance of the SuperStitch® devices by medical providers and the marketplace in general and the success of the proposed sales and marketing plan, the continued growth of the vessel closure marketplace and the company's ability to continue to expand and protect its technology patents.

Contact Information